Eptifibatide
Integrilin (eptifibatide) is a protein pharmaceutical. Eptifibatide was first approved as Integrilin on 1998-05-18. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA. It has been approved in Europe to treat myocardial infarction and unstable angina.
| Trade Name | Integrilin |
|---|---|
| Common Name | Eptifibatide |
| Indication | coronary disease, myocardial infarction, unstable angina |
| Drug Class | Peptides: platelet aggregation inhibitors (glycoprotein IIb/IIIa receptor antagonists) |
